Logo image of ORGO

ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

NASDAQ:ORGO - Nasdaq - US68621F1021 - Common Stock - Currency: USD

3.03  +0.02 (+0.66%)

Premarket: 3.18 +0.15 (+4.95%)

Fundamental Rating

6

ORGO gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. ORGO gets an excellent profitability rating and is at the same time showing great financial health properties. ORGO has a decent growth rate and is not valued too expensively. These ratings could make ORGO a good candidate for quality investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year ORGO was profitable.
ORGO had a positive operating cash flow in the past year.
Of the past 5 years ORGO 4 years were profitable.
In the past 5 years ORGO always reported a positive cash flow from operatings.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

ORGO has a Return On Assets of -0.19%. This is amongst the best in the industry. ORGO outperforms 90.04% of its industry peers.
With an excellent Return On Equity value of -0.24%, ORGO belongs to the best of the industry, outperforming 91.10% of the companies in the same industry.
ORGO has a Return On Invested Capital of 4.04%. This is amongst the best in the industry. ORGO outperforms 93.24% of its industry peers.
ORGO had an Average Return On Invested Capital over the past 3 years of 3.79%. This is significantly below the industry average of 14.31%.
The last Return On Invested Capital (4.04%) for ORGO is above the 3 year average (3.79%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -0.19%
ROE -0.24%
ROIC 4.04%
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

With an excellent Operating Margin value of 4.46%, ORGO belongs to the best of the industry, outperforming 93.06% of the companies in the same industry.
In the last couple of years the Operating Margin of ORGO has declined.
With an excellent Gross Margin value of 75.99%, ORGO belongs to the best of the industry, outperforming 83.27% of the companies in the same industry.
In the last couple of years the Gross Margin of ORGO has remained more or less at the same level.
Industry RankSector Rank
OM 4.46%
PM (TTM) N/A
GM 75.99%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ORGO is destroying value.
The number of shares outstanding for ORGO has been reduced compared to 1 year ago.
The number of shares outstanding for ORGO has been increased compared to 5 years ago.
Compared to 1 year ago, ORGO has an improved debt to assets ratio.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 3.55 indicates that ORGO is not in any danger for bankruptcy at the moment.
ORGO has a better Altman-Z score (3.55) than 78.11% of its industry peers.
ORGO has a debt to FCF ratio of 0.45. This is a very positive value and a sign of high solvency as it would only need 0.45 years to pay back of all of its debts.
The Debt to FCF ratio of ORGO (0.45) is better than 96.26% of its industry peers.
ORGO has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.00, ORGO perfoms like the industry average, outperforming 47.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Altman-Z 3.55
ROIC/WACC0.39
WACC10.45%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 3.69 indicates that ORGO has no problem at all paying its short term obligations.
The Current ratio of ORGO (3.69) is comparable to the rest of the industry.
ORGO has a Quick Ratio of 3.35. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 3.35, ORGO perfoms like the industry average, outperforming 40.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.69
Quick Ratio 3.35
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

ORGO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 125.00%, which is quite impressive.
Measured over the past years, ORGO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -37.90% on average per year.
The Revenue has grown by 11.29% in the past year. This is quite good.
The Revenue has been growing by 13.05% on average over the past years. This is quite good.
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%

3.2 Future

The Earnings Per Share is expected to grow by 3.54% on average over the next years.
Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 10.02% on average per year.
EPS Next Y-77.5%
EPS Next 2Y0%
EPS Next 3Y3.54%
EPS Next 5YN/A
Revenue Next Year4.27%
Revenue Next 2Y8.2%
Revenue Next 3Y10.02%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 33.67, which means the current valuation is very expensive for ORGO.
Compared to the rest of the industry, the Price/Earnings ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 93.24% of the companies listed in the same industry.
ORGO's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.05.
ORGO is valuated rather expensively with a Price/Forward Earnings ratio of 17.82.
Based on the Price/Forward Earnings ratio, ORGO is valued cheaper than 92.35% of the companies in the same industry.
ORGO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.07, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.67
Fwd PE 17.82
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ORGO is valued cheaply inside the industry as 98.75% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ORGO is valued cheaper than 93.06% of the companies in the same industry.
Industry RankSector Rank
P/FCF 92.04
EV/EBITDA 6.5
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3

4.3 Compensation for Growth

The decent profitability rating of ORGO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0%
EPS Next 3Y3.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ORGO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (5/15/2025, 8:00:02 PM)

Premarket: 3.18 +0.15 (+4.95%)

3.03

+0.02 (+0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-06 2025-08-06/amc
Inst Owners50.15%
Inst Owner Change-2.95%
Ins Owners30.6%
Ins Owner Change-12.26%
Market Cap384.36M
Analysts82
Price Target6.12 (101.98%)
Short Float %17.44%
Short Ratio6.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)629.41%
Min EPS beat(2)570.59%
Max EPS beat(2)688.24%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.53%
Min Revenue beat(2)3.75%
Max Revenue beat(2)13.3%
Revenue beat(4)4
Avg Revenue beat(4)7.13%
Min Revenue beat(4)3.75%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)3.01%
Revenue beat(12)5
Avg Revenue beat(12)0.76%
Revenue beat(16)8
Avg Revenue beat(16)2.27%
PT rev (1m)0%
PT rev (3m)20%
EPS NQ rev (1m)-13.34%
EPS NQ rev (3m)-1233.4%
EPS NY rev (1m)-28.57%
EPS NY rev (3m)150%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.24%
Valuation
Industry RankSector Rank
PE 33.67
Fwd PE 17.82
P/S 0.8
P/FCF 92.04
P/OCF 27.05
P/B 1
P/tB 1.12
EV/EBITDA 6.5
EPS(TTM)0.09
EY2.97%
EPS(NY)0.17
Fwd EY5.61%
FCF(TTM)0.03
FCFY1.09%
OCF(TTM)0.11
OCFY3.7%
SpS3.8
BVpS3.04
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.19%
ROE -0.24%
ROCE 5.12%
ROIC 4.04%
ROICexc 5.97%
ROICexgc 6.98%
OM 4.46%
PM (TTM) N/A
GM 75.99%
FCFM 0.87%
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexcg growth 3Y-38.4%
ROICexcg growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score6
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.45
Debt/EBITDA 0.02
Cap/Depr 58.92%
Cap/Sales 2.08%
Interest Coverage 4.33
Cash Conversion 36.86%
Profit Quality N/A
Current Ratio 3.69
Quick Ratio 3.35
Altman-Z 3.55
F-Score6
WACC10.45%
ROIC/WACC0.39
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)125%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%-400%
EPS Next Y-77.5%
EPS Next 2Y0%
EPS Next 3Y3.54%
EPS Next 5YN/A
Revenue 1Y (TTM)11.29%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%-21.17%
Revenue Next Year4.27%
Revenue Next 2Y8.2%
Revenue Next 3Y10.02%
Revenue Next 5YN/A
EBIT growth 1Y71.72%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year454.35%
EBIT Next 3Y72.88%
EBIT Next 5YN/A
FCF growth 1Y-36.27%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-54.04%
OCF growth 3Y-38.8%
OCF growth 5YN/A